• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pardes Biosciences Inc. (Amendment)

    2/8/23 5:09:28 PM ET
    $PRDS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PRDS alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
    Pardes Biosciences Inc 

    (Name of Issuer)
     
    Common stock, par value $0.0001 per share

    (Title of Class of Securities)
     
    69945Q105

    (CUSIP Number)
     
    Calendar Year 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  69945Q105      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BML Investment Partners, L.P.
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     4,867,984
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     4,867,984
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     4,867,984
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     7.8%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     PN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    Pardes Biosciences Inc

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    2173 Salk Avenue, Suite 250

    PMB#052

    Carlsbad, CA

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    BML Investment Partners, L.P.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    65 E Cedar - Suite 2
    Zionsville, IN 46077

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common stock, par value $0.0001 per share

     
    (e)
    CUSIP Number
     
     
    69945Q105

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 4,867,984

     
    (b)
    Percent of class: 7.8%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 4,867,984

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 4,867,984

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BML Capital Management, LLC
     
        
    Date: February 08, 2023
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       Title:  Managing Member 
        
     
    Footnotes:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M.Leonard. As a result, Braden M.Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Exchange Act.

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $PRDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRDS

    DatePrice TargetRatingAnalyst
    7/18/2023Mkt Outperform → Mkt Perform
    JMP Securities
    3/15/2022Outperform
    SVB Leerink
    1/18/2022$25.00Buy
    Jefferies
    More analyst ratings

    $PRDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pardes Biosciences Announces Closing of Tender Offer

      CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

      8/31/23 8:15:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

      As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (NASDAQ:PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the "CVR") associated with any future monetization of Pardes' COVID-19 antiviral portfolio and related intellectual property. Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes' out

      8/28/23 11:33:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

      As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (NASDAQ:PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share (the "Additional Price Per Share"), plus a non-tradeable contingent value right (the "CVR") associated with any future monetization of Pardes' COVID-19 antiviral portfolio and related intellectual property. Pursua

      8/17/23 5:43:00 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)

      SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      8/31/23 5:17:40 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Pardes Biosciences Inc.

      SC 13G - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      8/14/23 4:31:01 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)

      SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      7/17/23 7:55:13 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 5:22:32 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Wiggans Thomas G closing all direct ownership in the company

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 2:55:56 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Varney Michael David closing all direct ownership in the company

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 2:54:23 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Financials

    Live finance-specific insights

    See more
    • Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022

      PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Company to host conference call and webcast Tuesday, February 15, 2022 at 3:00 p.m. PT / 6:00 p.m. ET CARLSBAD, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that interim clin

      2/14/22 7:30:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pardes Biosciences to Host Virtual Investor Event

      CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a virtual investor event will be hosted by the company's management team following the presentation of clinical data from the ongoing PBI-0451 Phase 1 trial at the 29th Conference On Retroviruses And Opportunistic Infections (CROI) 2022. The conference call and webcast will take place on Tuesday, February 15 at 3:00 p.m. PT / 6:00 p.m. ET. Individuals in

      2/9/22 7:00:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Leadership Updates

    Live Leadership Updates

    See more
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors

      CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today announced the appointments of Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to its Board of Directors. "As we advance PBI-0451 into a Phase 2 study, I am delighted to welcome both Laurie and John to our Board and look forward to leveraging their deep experience and insights as we take the next steps in development," said Tom Wiggans, Chief Executive Officer and Chair of the B

      9/14/22 8:00:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board

      Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be beneficial to Pardes as the company rapidly progresses to late-stage development and regulatory activities, as well as the initial phases of commercialization build-out Uri Lopatin, M.D. to transition to Chief Scientific & Strategic Advisor; Mark Auerbach to transition from Chairman to Board Director CARLSBAD, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral a

      3/2/22 4:30:00 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PRDS
    SEC Filings

    See more
    • Pardes Biosciences downgraded by JMP Securities

      JMP Securities downgraded Pardes Biosciences from Mkt Outperform to Mkt Perform

      7/18/23 7:42:34 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SVB Leerink initiated coverage on Pardes Biosciences

      SVB Leerink initiated coverage of Pardes Biosciences with a rating of Outperform

      3/15/22 10:07:39 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on Pardes Biosciences with a new price target

      Jefferies initiated coverage of Pardes Biosciences with a rating of Buy and set a new price target of $25.00

      1/18/22 8:36:11 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Pardes Biosciences Inc.

      15-12G - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/11/23 8:00:13 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:04 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:24 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care